One company in particular, Prana Biotechnology (NASDAQ:PRAN), is well-positioned to address this market with their lead drug, and in a realistic but optimistic scenario, the share price could ducuple (increase by 10 times) by the end of the month.
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) sank 70.49% early Monday after the Australian drug developer said its most advanced potential treatment failed to meet the main goal in a study of patients with Alzheimer's disease.
Prana is working under a different hypothesis. It, along with a growing number of scientists, now think that small beta-amyloid oligomers are the real culprits in Alzheimer's disease, because they have been found to float into synapses and short ...
Alzheimer's Dementia is a terrible and costly disease and currently the treatments for it are poor. Solanezumab and PBT2 have both shown that they may help the cognitive decline seen in Alzheimer's Dementia.